Xarelto licensed to treat pulmonary embolism

Xarelto (rivaroxaban) can now be prescribed for the treatment of pulmonary embolism (PE) in adults.

Rivaroxaban is not recommended in patients with PE who are haemodynamically unstable or who are candidates for thrombolysis or pulmonary embolectomy.
Rivaroxaban is not recommended in patients with PE who are haemodynamically unstable or who are candidates for thrombolysis or pulmonary embolectomy.

The direct factor Xa inhibitor is also indicated for the treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and PE, prevention of stroke and systemic embolism in non-valvular atrial fibrillation, and prevention of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery.

Study design

The open-label EINSTEIN-PE study investigated the use of rivaroxaban in the treatment of acute symptomatic PE with or without DVT. Participants (n=4832) were randomised to receive either rivaroxaban (15mg twice daily for three weeks, followed by 20mg once daily) or standard therapy (enoxaparin 1mg/kg twice daily followed by dose-adjusted warfarin or acenocoumarol to maintain an INR of 2.0–3.0). Treatment continued for 3, 6 or 12 months, as determined by the treating physician.

Non-inferior to enoxaparin/warfarin regimen

Intention-to-treat analysis showed that rivaroxaban was non-inferior to standard therapy (p=0.003) in terms of symptomatic recurrent VTE (the primary efficacy end point), which occurred in 2.1% of patients in the rivaroxaban group and 1.8% of those in the standard therapy group (hazard ratio 1.12, 95% CI 0.75–1.68).

No difference in primary safety outcome over standard treatment

There was no significant difference in the rate of major or clinically relevant non-major bleeding (the primary safety outcome) between the two groups. However, major bleeding was significantly reduced with rivaroxaban: 1.1% vs 2.2% (hazard ratio 0.49, 95% CI 0.31–0.79, p=0.003).

View Xarelto drug record

Further information: Bayer plc

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

A head shot of a smiling Dr Richard Russell.

Free webinar: are COPD and CVD ‘two sides of the same coin’?

MIMS Learning is hosting a free webinar on 13 June...